Spark Therapeutics, Inc. (ONCE) PT Set at $89.00 by BMO Capital Markets

Spark Therapeutics, Inc. (NASDAQ:ONCE) received a $89.00 price objective from BMO Capital Markets in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the biotechnology company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 3.25% from the stock’s previous close.

Other equities research analysts have also issued research reports about the stock. Chardan Capital raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $60.00 to $100.00 in a report on Wednesday, August 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $85.00 price target on shares of Spark Therapeutics in a report on Monday, July 24th. Cantor Fitzgerald set a $94.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, July 17th. UBS AG reissued a “buy” rating and issued a $92.00 price target (up previously from $70.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $92.00 price target (up previously from $77.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seventeen have given a buy rating to the stock. Spark Therapeutics has a consensus rating of “Buy” and an average price target of $88.38.

Spark Therapeutics (NASDAQ ONCE) opened at 86.20 on Tuesday. The firm’s market cap is $2.69 billion. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $91.00. The company has a 50-day moving average of $85.91 and a 200 day moving average of $85.91.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. Spark Therapeutics’s revenue was up 14.7% on a year-over-year basis. During the same period last year, the business earned ($1.04) EPS. Equities analysts expect that Spark Therapeutics will post ($7.67) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Spark Therapeutics, Inc. (ONCE) PT Set at $89.00 by BMO Capital Markets” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/10/12/spark-therapeutics-inc-once-pt-set-at-89-00-by-bmo-capital-markets.html.

In related news, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total transaction of $430,800.00. Following the completion of the transaction, the insider now directly owns 215,000 shares of the company’s stock, valued at approximately $18,524,400. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Katherine A. High sold 10,000 shares of Spark Therapeutics stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $72.53, for a total transaction of $725,300.00. Following the transaction, the insider now directly owns 220,000 shares of the company’s stock, valued at $15,956,600. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,333,195 shares of company stock valued at $109,070,506. Corporate insiders own 7.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC lifted its position in Spark Therapeutics by 0.9% during the 1st quarter. FMR LLC now owns 4,656,655 shares of the biotechnology company’s stock valued at $248,386,000 after acquiring an additional 40,698 shares during the period. BlackRock Inc. lifted its position in Spark Therapeutics by 11.6% during the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after acquiring an additional 213,520 shares during the period. Vanguard Group Inc. lifted its position in Spark Therapeutics by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after acquiring an additional 96,803 shares during the period. JPMorgan Chase & Co. lifted its position in Spark Therapeutics by 3.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,607,972 shares of the biotechnology company’s stock valued at $96,060,000 after acquiring an additional 58,879 shares during the period. Finally, Wellington Management Group LLP lifted its position in Spark Therapeutics by 119.5% during the 1st quarter. Wellington Management Group LLP now owns 808,782 shares of the biotechnology company’s stock valued at $43,140,000 after acquiring an additional 440,287 shares during the period. 77.84% of the stock is owned by institutional investors.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply